# Viking Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Viking Therapeutics, Inc.). ## Overview Viking Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Its pipeline includes oral and injectable drug candidates such as VK2735, VK2809, VK0214, and VK5211, with research and development centered in San Diego, California. ## Products & services • VK2735 oral and subcutaneous obesity therapy • VK2809 oral thyroid hormone receptor beta agonist • VK0214 metabolic/endocrine drug candidate • VK5211 investigational therapeutic program • Clinical development and regulatory advancement - **VK2735** (40%) — Dual GLP-1/GIP receptor agonist being developed in oral and subcutaneous forms for obesity and related metabolic disorders. - **VK2809** (25%) — Oral thyroid hormone receptor beta agonist being developed for NASH/MASH and other metabolic liver disorders. - **VK0214** (15%) — Investigational program targeting metabolic and endocrine disease pathways. - **VK5211** (10%) — Additional preclinical or clinical-stage therapeutic program within the company’s pipeline. - **Clinical development and manufacturing** (10%) — Research, clinical trial execution, and manufacturing preparation across the pipeline. - VK2735 oral and subcutaneous obesity therapy - VK2809 oral thyroid hormone receptor beta agonist - VK0214 metabolic/endocrine drug candidate - VK5211 investigational therapeutic program - Clinical development and regulatory advancement ## Customers Viking does not yet sell approved products; its near-term counterparties are clinical trial participants, investigators, CROs, manufacturers, and potential licensing or commercialization partners. If approved, its eventual customers would be physicians, patients, and healthcare payors in obesity and metabolic disease markets. - **Clinical trial ecosystem** (primary) — Patients, investigators, CROs, and trial sites that support testing of VK2735, VK2809, and other programs. - **Manufacturing partners** (primary) — Third-party API and fill/finish providers that produce clinical and future commercial supply. - **Potential licensing and commercialization partners** (secondary) — Biopharma partners that may help fund development, market products, or provide commercial infrastructure. - **Future obesity and metabolic disease patients** (emerging) — Patients who would use approved therapies for obesity, NASH/MASH, and related disorders. - **Healthcare payors and providers** (emerging) — Physicians and payors that would determine adoption, access, and reimbursement after approval. - Clinical trial participants enrolled in Phase 1, Phase 2, and Phase 3 studies - Investigators, CROs, and trial sites running the development program - Manufacturing partners supplying API, fill/finish, and device capacity - Potential pharma collaborators or licensees for commercialization - Future physicians, patients, and payors if products reach market ## Geography Viking is headquartered in San Diego, California and conducts its research and development from the United States. Its business is primarily U.S.-based, while clinical development, manufacturing, and any future commercialization could involve third-party partners and trial sites in multiple countries. - Headquartered in San Diego, California - Core research and development operations are in the United States - Clinical trials may use sites outside the U.S. through CRO networks - Manufacturing is outsourced to third-party partners, including CordenPharma - Future commercialization geography will depend on regulatory approvals ## Strategy Viking’s strategy is to advance a focused pipeline of metabolic and endocrine drug candidates through clinical development, with VK2735 as the lead program. It is also building manufacturing capacity and optionality so that, if approved, it can support larger-scale supply and potential commercialization or partnering. - **Advance VK2735 through clinical development** (short-term) — The lead obesity program is the main value driver and the most advanced asset in the pipeline. - **Build oral and injectable product options** (medium-term) — Multiple formulations can broaden patient access and improve commercial flexibility if approved. - **Secure scalable manufacturing** (short-term) — Dedicated API and fill/finish capacity is needed to support late-stage trials and potential launch supply. - **Maintain pipeline breadth beyond VK2735** (medium-term) — Additional assets reduce single-asset dependence and create future partnering or development options. - Advance VK2735 through late-stage clinical development - Develop both oral and injectable formulations for flexibility - Progress VK2809 and other pipeline assets in parallel - Secure manufacturing capacity for future clinical and commercial supply - Preserve partnering optionality for commercialization and funding ## Risks Viking is a clinical-stage company with no approved products, so its value depends heavily on clinical, regulatory, and manufacturing execution. It also relies on licensed technology and third-party partners, which creates concentration risk if trials fail, approvals are delayed, or supply arrangements do not perform as expected. - **Clinical development failure or delay** [critical] — The company’s pipeline is still in development, so negative trial results or slow enrollment can materially reduce value. - **Dependence on licensed technology from Ligand** [high] — Loss or restriction of the master license agreement would impair the ability to develop current and future candidates. - **Manufacturing and supply execution risk** [high] — Late-stage trials and future launch require reliable API, fill/finish, and device supply at scale. - **Financing risk** [high] — The company expects continued losses and may need additional capital to complete development and commercialization. - **Commercial adoption and reimbursement risk** [medium] — Even if approved, uptake depends on efficacy, safety, convenience, and payor coverage in competitive obesity markets. - No approved products, so revenue depends on future clinical success - Clinical trials may fail, be delayed, or produce unfavorable data - Dependence on Ligand-licensed technology creates IP and access risk - Manufacturing and supply chain execution can constrain development - Future commercialization depends on reimbursement and market acceptance ## Accounting The main accounting judgments are development-stage cost estimates, stock-based compensation, and the treatment of manufacturing prepayments and other third-party commitments. Because the company has no product revenue, reported results are driven by R&D expense timing, fair-value-based equity compensation, and interest income on cash and investments. - **Research and development cost estimation** — R&D expense and accrued liabilities - **Stock-based compensation** — G&A and R&D expense - **Manufacturing prepayments** — Cash, prepaid assets, and future supply costs - **Deferred tax assets and valuation allowance** — Income tax provision and balance sheet valuation allowance - R&D expense estimates depend on clinical and manufacturing activity timing - Stock-based compensation affects operating expense and employee retention costs - Manufacturing prepayments may be capitalized and later credited against orders - No product revenue yet, so results are dominated by expense recognition timing - Deferred tax assets likely depend on valuation allowance judgments --- *Last updated: 2026-04-29T05:08:06.816227+00:00*